Next step approval for emergency use authorization from the Food & Drug Administration. Today, Thursday, December 17, a FDA advisory committee voted 20 to 0, with one abstention, that the benefits of the Moderna (MRNA) coronavirus vaccine outweigh any risk.
Dividend Stock Portfolio member CVS Health (CVS) has set  December 21 for the start of its program to vaccinate residents of long-term care facilities with the Pfizer (PFE) vaccine expected to be approved today for emergency use.
Dow (DOW) certainly fits the dividend template that I’ve explained in my Special Report: “10 Dividend Stocks that are beating the risky rockets. The stock yields 5.26% after a 0.20% gain today December 9. That compares to a yield of just 2.8% in July 2017 and 3.1% in December 2016. The stock also shows a 1.06% price to sales ratio on today. I think we’re looking at a cheap stock. Tomorrow I’l be adding it to my Dividend Portfolio.
I’m adding Citigroup, the most recent pick in my Dividend Stocks Special Report, to my Dividend Portfolio tomorrow
For 2020 as of the close on December 1, the total return for Dividend Portfolio was 14.19%. The dividend yield, so far, works out to 2.96%. That’s deceptively low, however, since most of the stocks in the portfolio haven’t completed their dividend payments for the year.
In 2018 my Dividend Portfolio showed a yield on 3.60%. That produced $6,483 in dividend income that year. The goal of this portfolio is to beat the yield on the 10-year Treasury. On January 1, 2018 the yield on the 10-year Treasury was 2.58%. In 2019 my Dividend Portfolio showed a yield of 4.90%
Last night, I made Duke Energy (DUK) my second pick in my Special Report: “Dividend Stocks that are beating the Risky Rockets.” Today November 19, I’m adding these shares to my Dividend Portfolio.
I started off with utility stocks and I’ve now moved on to other dividend stocks within the general argument that dividend stocks–if you pick the right one–are perfect for the post-vaccine economy and stock market rally.
